PT2389937T - Composição farmacêutica para melhorar as funções cerebrais - Google Patents

Composição farmacêutica para melhorar as funções cerebrais

Info

Publication number
PT2389937T
PT2389937T PT11006318T PT11006318T PT2389937T PT 2389937 T PT2389937 T PT 2389937T PT 11006318 T PT11006318 T PT 11006318T PT 11006318 T PT11006318 T PT 11006318T PT 2389937 T PT2389937 T PT 2389937T
Authority
PT
Portugal
Prior art keywords
cerebral
ingredient
integer
optionally substituted
hydroxyl group
Prior art date
Application number
PT11006318T
Other languages
English (en)
Inventor
Ono Satoshi
Nakagawa Masaya
Nakada Yasushi
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of PT2389937T publication Critical patent/PT2389937T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PT11006318T 2002-06-14 2003-04-03 Composição farmacêutica para melhorar as funções cerebrais PT2389937T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002173483 2002-06-14

Publications (1)

Publication Number Publication Date
PT2389937T true PT2389937T (pt) 2018-10-26

Family

ID=29727916

Family Applications (2)

Application Number Title Priority Date Filing Date
PT11006318T PT2389937T (pt) 2002-06-14 2003-04-03 Composição farmacêutica para melhorar as funções cerebrais
PT03760132T PT1514542E (pt) 2002-06-14 2003-04-03 Composição medicamentosa incluindo tacrina ou donepezilo para melhorar as funções cerebrais

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT03760132T PT1514542E (pt) 2002-06-14 2003-04-03 Composição medicamentosa incluindo tacrina ou donepezilo para melhorar as funções cerebrais

Country Status (23)

Country Link
US (3) USRE42327E1 (pt)
EP (2) EP2389937B1 (pt)
JP (1) JP4675103B2 (pt)
KR (1) KR100935615B1 (pt)
CN (1) CN100375619C (pt)
AT (1) ATE546140T1 (pt)
AU (1) AU2003236364C1 (pt)
BR (1) BRPI0311780B8 (pt)
CA (1) CA2488120C (pt)
CY (2) CY1112958T1 (pt)
DK (2) DK1514542T3 (pt)
ES (2) ES2379948T3 (pt)
HU (1) HUE041842T2 (pt)
IL (1) IL165589A (pt)
MX (1) MXPA04012534A (pt)
NO (1) NO333504B1 (pt)
NZ (1) NZ537090A (pt)
PL (1) PL217394B1 (pt)
PT (2) PT2389937T (pt)
SI (2) SI2389937T1 (pt)
TR (1) TR201816386T4 (pt)
WO (1) WO2003105830A1 (pt)
ZA (1) ZA200409901B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002344107B2 (en) * 2001-10-19 2007-11-01 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof
IL165589A (en) 2002-06-14 2012-04-30 Toyama Chemical Co Ltd Pharmaceutical preparation to improve brain function and use
EP1614419B1 (en) * 2003-04-17 2012-08-08 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
EP2258359A3 (en) * 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
SI2011796T1 (sl) * 2006-04-26 2015-02-27 Toyama Chemical Co., Ltd. Induktor nevrogeneze ali terapevtska uäśinkovina proti nevropatiji, vsebujoäśa derivat alkilnega etra ali sol le-tega
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
CA2659835A1 (en) * 2006-08-04 2008-02-07 Toyama Chemical Co., Ltd. Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
US8026232B2 (en) * 2008-05-28 2011-09-27 Toyama Chemical Co., Ltd. Benzothiophene oxide derivative and salt thereof
CA2908929C (en) 2012-07-12 2021-01-26 Concert Pharmaceuticals, Inc. Deuterated idebenone
LT3100725T (lt) 2014-01-31 2020-08-10 Fujifilm Toyama Chemical Co., Ltd. Reabilitacijos poveikį po nervo pažeidimo sustiprinanti priemonė, apimanti alkileterio darinį arba jo druską
US11666551B2 (en) 2017-06-02 2023-06-06 Fujifilm Toyama Chemical Co., Ltd. Agent for reducing amount of amyloid β protein
WO2018221728A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アルツハイマー型認知症予防または治療剤
AU2018277981B2 (en) 2017-06-02 2021-04-08 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
CA3067456C (en) 2017-06-02 2023-03-14 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating tauopathy
NZ759585A (en) 2017-06-02 2022-02-25 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating brain atrophy
KR20200024854A (ko) * 2017-07-08 2020-03-09 더 제너럴 하스피탈 코포레이션 알츠하이머 질환의 치료를 위한 치료 약물 또는 제제를 확인하기 위한 스크리닝 플랫폼
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用
CN110464834B (zh) * 2019-09-04 2022-12-02 北京豪思生物科技股份有限公司 铜蓝蛋白联合多奈哌齐的应用
KR20220040291A (ko) 2020-09-23 2022-03-30 씨엔지바이오 주식회사 4-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물
KR20220040294A (ko) 2020-09-23 2022-03-30 씨엔지바이오 주식회사 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US5177082A (en) 1985-11-05 1993-01-05 Yu Chao Mei Huperzines and analogs
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JPH0210827A (ja) 1988-06-29 1990-01-16 Matsushita Electron Corp 半導体装置の製造方法
NZ232493A (en) * 1989-02-14 1992-06-25 Toyama Chemical Co Ltd Aryl- or heterocyclyl-substituted 1,2-ethanediol derivatives and pharmaceutical compositions
US5280032A (en) 1989-02-14 1994-01-18 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
JP2913196B2 (ja) 1989-04-26 1999-06-28 富山化学工業株式会社 １，２−エタンジオール誘導体またはその塩
JP2887492B2 (ja) 1990-02-05 1999-04-26 富山化学工業株式会社 １，２―エタンジオール誘導体およびその塩
US4914102A (en) * 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
JP3044055B2 (ja) 1990-08-09 2000-05-22 富山化学工業株式会社 １，２―エタンジオール誘導体およびその塩
JPH0676401B2 (ja) 1990-10-19 1994-09-28 エスエス製薬株式会社 キノリン誘導体及びこれを含有する医薬
TW197435B (pt) 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
DE4111861A1 (de) 1991-04-11 1992-10-15 Schwabe Willmar Gmbh & Co Benzopyranone, verfahren zu ihrer herstellung und verwendung
JP2925363B2 (ja) 1991-07-09 1999-07-28 キヤノン株式会社 画像処理方法及び装置
DE4136288A1 (de) 1991-11-04 1993-05-06 Troponwerke Gmbh & Co Kg, 5000 Koeln, De Kombination von calciumantagonisten mit cholinesterase-inhibitoren
JP3232830B2 (ja) 1993-11-30 2001-11-26 三菱電機株式会社 フレキシブルディスク装置のキャリッジ機構
PL187490B1 (pl) 1994-10-25 2004-07-30 Toyama Chemical Co Ltd Zastosowanie pochodnej 1,2-etanodiolu lub jej soli do wytwarzania środka wzmacniającego aktywność czynnika wzrostowego nerwu
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
AU1672597A (en) * 1996-02-20 1997-09-10 Toyama Chemical Co. Ltd. Cerebral function ameliorant containing 1,2-ethanediol derivatives or salts thereof
ATE227708T1 (de) * 1996-07-10 2002-11-15 Schering Corp 1,4-disubstituierte piperdine als muskarin- antagonisten
CA2263167C (en) * 1996-08-15 2006-02-14 Schering Corporation Ether muscarinic antagonists
JPH10259126A (ja) 1997-01-17 1998-09-29 Takeda Chem Ind Ltd アルツハイマー病治療・予防剤
US20030092737A1 (en) 1997-11-14 2003-05-15 Pierre Maffrand Jean Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
CO4980891A1 (es) 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
AU1506499A (en) 1997-12-12 1999-07-05 Toyama Chemical Co. Ltd. Alkyl ether derivatives or salts thereof and calcium antagonists containing the same
AU770234B2 (en) 1999-06-11 2004-02-19 Toyama Chemical Co. Ltd. N-alkoxyalkyl-N, N-dialkylamine derivatives or salts thereof and agents for treating neurodegenerative diseases comprising the same
AU2002344107B2 (en) 2001-10-19 2007-11-01 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof
IL165589A (en) 2002-06-14 2012-04-30 Toyama Chemical Co Ltd Pharmaceutical preparation to improve brain function and use
EP1614419B1 (en) 2003-04-17 2012-08-08 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
US8119625B2 (en) 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
SI2011796T1 (sl) 2006-04-26 2015-02-27 Toyama Chemical Co., Ltd. Induktor nevrogeneze ali terapevtska uäśinkovina proti nevropatiji, vsebujoäśa derivat alkilnega etra ali sol le-tega

Also Published As

Publication number Publication date
NO333504B1 (no) 2013-06-24
BRPI0311780B8 (pt) 2021-05-25
KR20050010877A (ko) 2005-01-28
WO2003105830A1 (ja) 2003-12-24
EP2389937B1 (en) 2018-08-15
CY1120591T1 (el) 2019-12-11
BR0311780A (pt) 2005-03-15
EP1514542B1 (en) 2012-02-22
NO20045158L (no) 2005-03-10
KR100935615B1 (ko) 2010-01-07
CA2488120A1 (en) 2003-12-24
CA2488120C (en) 2012-04-17
EP2389937A1 (en) 2011-11-30
SI2389937T1 (sl) 2018-10-30
IL165589A (en) 2012-04-30
EP1514542A1 (en) 2005-03-16
DK2389937T3 (en) 2018-11-12
AU2003236364A1 (en) 2003-12-31
CN100375619C (zh) 2008-03-19
NZ537090A (en) 2006-02-24
PT1514542E (pt) 2012-03-27
JP4675103B2 (ja) 2011-04-20
ATE546140T1 (de) 2012-03-15
PL217394B1 (pl) 2014-07-31
JPWO2003105830A1 (ja) 2005-10-13
EP1514542A4 (en) 2009-06-03
AU2003236364B2 (en) 2008-08-21
AU2003236364C1 (en) 2009-12-24
TR201816386T4 (tr) 2018-11-21
BRPI0311780B1 (pt) 2017-09-26
US7342043B2 (en) 2008-03-11
US20080103126A1 (en) 2008-05-01
SI1514542T1 (sl) 2012-06-29
CY1112958T1 (el) 2016-04-13
ES2685923T3 (es) 2018-10-15
MXPA04012534A (es) 2005-04-19
CN1662232A (zh) 2005-08-31
USRE42327E1 (en) 2011-05-03
PL372934A1 (en) 2005-08-08
US7834053B2 (en) 2010-11-16
US20050250843A1 (en) 2005-11-10
ES2379948T3 (es) 2012-05-07
ZA200409901B (en) 2006-07-26
DK1514542T3 (da) 2012-04-10
HUE041842T2 (hu) 2019-05-28
IL165589A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
CY1120591T1 (el) Ιατρικη συνθεση για βελτιωση λειτουργιας εγκεφαλου
BG105365A (en) Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
NO20024042D0 (no) Aryl-fusjonerte azapolysykliske forbindelser
UA83899C2 (uk) Сполуки імідазолу для лікування нейродегенеративних розладів
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
MY140835A (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
CA2534532A1 (en) Compounds for the treatment of neurodegenerative disorders
DK0628548T3 (da) 1,2,3,4-Tetraydro-acridinamin-derivater
WO2005095348A3 (en) Pyrazole-amine compounds for the treatment of neurodegenerative disorders
DE60231054D1 (de) Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält
DE69822937D1 (de) Indolmorphinan-derivate und medikamente zur behandlung/mittel zur vorbeugung von cerebralen störungen
ZA891769B (en) Heterocyclic compounds
WO2005095361A8 (en) Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
DK0950053T3 (da) Hidtil ukendte benzoylalkyl.1,2,3,6-tetrahydropyridinderivater